Search | IOVS | ARVO Journals

View

Showing 1 – 20 of 25

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

Occurrence of steroid-associated adverse events with loteprednol etabonate formulations

Megan E Cavet; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):720. doi:

ARVO Annual Meeting Abstract June 2021

Interim Analysis of Antibiotic Resistance from Bacterial Pathogens Collected in the 2020 ARMOR Study

Christine M Sanfilippo; Heleen H DeCory; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):717. doi:

ARVO Annual Meeting Abstract June 2021

Analysis of Longitudinal Antibiotic Susceptibility Trends in Staphylococci: Results from 12 Years of the ARMOR Study

Penny A Asbell; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2684. doi:

ARVO Annual Meeting Abstract June 2021

In Vitro Potency of Tobramycin Against Common Bacterial Pathogens Implicated in Blepharitis

James E Deom; Megan E Cavet; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):414. doi:

ARVO Annual Meeting Abstract June 2021

Comparative In Vitro Activity of Antibiotics Frequently Used in the Management of Staphylococcal Blepharitis

Robert F Kissling; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):730. doi:

ARVO Annual Meeting Abstract June 2020

In Vitro Antibiotic Resistance of Ocular Bacterial Pathogens – An Update from the 2019 ARMOR Study

Christine M Sanfilippo; Heleen DeCory; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2978. doi:

ARVO Annual Meeting Abstract June 2020

Trends in Antibiotic Resistance Over Time Among Staphylococci Collected 2009-2019 in the ARMOR Study

Penny A Asbell; Christine M Sanfilippo; Heleen DeCory

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4885. doi:

ARVO Annual Meeting Abstract July 2019

Incidence of Polybacterial Infections in Three Bacterial Conjunctivitis Studies and Outcomes with Besifloxacin Ophthalmic Suspension 0.6%

Joseph M Blondeau; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):245. doi:

ARVO Annual Meeting Abstract July 2019

Antibiotic Resistance Among Ocular Pathogens – An Update from the 2018 ARMOR Study

Christine M Sanfilippo; Heleen H DeCory; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):246. doi:

ARVO Annual Meeting Abstract July 2019

Longitudinal Trends in Antibiotic Resistance Among Staphylococci Collected in the ARMOR Study

Penny A Asbell; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):853. doi:

ARVO Annual Meeting Abstract July 2018

Antibiotic Resistance in Ocular Pathogens – Preliminary Results from the 2017 ARMOR Surveillance Program

Christine M Sanfilippo; Megan E Cavet; Heleen DeCory; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2659. doi:

ARVO Annual Meeting Abstract July 2018

Antibiotic Resistance Trends Among Staphylococci in the ARMOR Study: 2009-2017

Penny A Asbell; Christine M Sanfilippo; Megan E Cavet; Heleen DeCory

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3676. doi:

ARVO Annual Meeting Abstract June 2017

Eight-Year Longitudinal Trends in Methicillin Resistance and Resistance to Other Antibiotics Among Staphylococci From the ARMOR Surveillance Study

Heleen H DeCory; Christine M Sanfilippo; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3874. doi:

ARVO Annual Meeting Abstract June 2017

Assessment of ophthalmic steroid class adverse event reports for loteprednol etabonate

Megan E Cavet; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1082. doi:

ARVO Annual Meeting Abstract June 2017

Antibiotic Resistance in Ocular Pathogens – An Update from the 2016 ARMOR Surveillance Program

Christine M Sanfilippo; Heleen H DeCory; Daniel F Sahm; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1083. doi:

ARVO Annual Meeting Abstract September 2016

Antibiotic Resistance Profiles of Ocular Pathogens – An Update from the 2015 ARMOR Surveillance Study

Christine M Sanfilippo; Heleen H DeCory; Daniel F Sahm; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5404. doi:

ARVO Annual Meeting Abstract September 2016

In Vitro Antibiotic Susceptibility of Ocular Pathogens Collected from the Aqueous and Vitreous Humor during the ARMOR Surveillance Study

Penny A Asbell; Heleen H DeCory; Daniel F Sahm; Christine M Sanfilippo

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2348. doi:

ARVO Annual Meeting Abstract September 2016

Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure

Megan E Cavet; Heleen H DeCory; John D Sheppard

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5405. doi:

ARVO Annual Meeting Abstract June 2015

Antibiotic Resistance Among Ocular Pathogens - Results from the ARMOR Surveillance Study 2013-Present

Penny A Asbell; Christine M Sanfilippo; Daniel F Sahm; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):284. doi:

ARVO Annual Meeting Abstract June 2015

Zylet (loteprednol etabonate 0.5%/tobramycin 0.3%) Compared with Tobradex (dexamethasone 0.1%/tobramycin 0.3%) for the treatment of blepharitis in a large international population

Timothy Comstock; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4867. doi:

1 2

Next 20 Results »

Advertisement